Westfield Capital Management
CLVS

Westfield Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Westfield Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-806,465
Closed -$20M – 275
2019
Q1 		$20M Buy
+806,465
New +$20.2M 0.15% 175
2018
Q4 		– Sell
-653,658
Closed -$19.2M – 279
2018
Q3 		$19.2M Sell
653,658
-148,410
-19% -$5.75M 0.13% 183
2018
Q2 		$36.5M Buy
802,068
+251,753
+46% +$12.2M 0.27% 121
2018
Q1 		$29.1M Buy
550,315
+44,760
+9% +$2.61M 0.22% 146
2017
Q4 		$34.4M Buy
505,555
+46,085
+10% +$3.22M 0.26% 144
2017
Q3 		$37.9M Buy
459,470
+144,300
+46% +$11.4M 0.29% 121
2017
Q2 		$29.5M Sell
315,170
-60,360
-16% -$3.69M 0.25% 130
2017
Q1 		$23.9M Sell
375,530
-53,655
-13% -$3.26M 0.21% 146
2016
Q4 		$19.1M Buy
+429,185
New +$15.1M 0.17% 173
2016
Q2 		– Sell
-347,660
Closed -$6.67M – 289
2016
Q1 		$6.67M Buy
+347,660
New +$7.36M 0.05% 202

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Westfield Capital Management's CLVS Position: Q2 2019 in Review

Westfield Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 806,465 shares — an estimated $20M sold.

Westfield Capital Management first reported a position in CLVS in Q1 2016 and held it in 10 quarters. The position peaked at $37.9M in Q3 2017. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Westfield Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Westfield Capital Management sold 806,465 Clovis Oncology, Inc. shares in Q2 2019, an estimated $20M.
  • Westfield Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 10 quarters.
  • Westfield Capital Management's Clovis Oncology, Inc. position peaked at $37.9M in Q3 2017.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Westfield Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.